The effect of bosentan on exercise capacity in Fontan patients; rationale and design for the TEMPO study

Anders Hebert, Annette S Jensen, Lars Idorn, Keld E Sørensen, Lars Søndergaard, Anders Hebert, Annette S Jensen, Lars Idorn, Keld E Sørensen, Lars Søndergaard

Abstract

Background: Palliative treatment with the Fontan procedure has greatly improved survival for children with functionally univentricular heart. Since Fontan performed the first successful operation, the procedure has evolved and is now performed as Total Cavo-Pulmonary Connection (TCPC).An increasing prevalence and longer life expectancy of TCPC patients have raised new challenges. The survivors are often suffering complications such as arrhythmias, myocardial dysfunction, thromboembolic events, neuropsychological deficit, protein-losing enteropathy and reduced exercise capacity. Several causes for the reduced exercise capacity may be present e.g. impaired function of the single ventricle, valve dysfunction and chronotropic impairment, and perhaps also increased pulmonary vascular resistance. Thus, plasma endothelin-1 has been shown to correlate with increased pulmonary vascular resistance and the risk of failing Fontan circulation. This has raised the question of the role for pulmonary vasodilation therapy, especially endothelin receptor antagonist in the management of TCPC patients.

Methods/design: The TEMPO trial aims to investigate whether Bosentan, an endothelin receptor antagonist, can be administered safely and improve exercise capacity in TCPC patients. The trial design is randomized, double-blind and placebo-controlled. Bosentan/placebo is administered for 14 weeks with control visits every four weeks. The primary endpoint is change in maximal oxygen consumption as assessed on bicycle ergometer test. Secondary endpoints include changes in pulmonary blood flow during exercise test, pro brain natriuretic peptide and quality of life.

Discussion: We hypothesize that treatment with Bosentan, an endothelin receptor antagonist, can be administered safely and improve exercise capacity in TCPC patients.

Trial registration: ClinicalTrials.gov NCT01292551.

Figures

Figure 1
Figure 1
Study design. b.i.d.: twice daily, Cont.: continue.

References

    1. Samánek M. Children with congenital heart disease: probability of natural survival. Pediatr Cardiol. 1992;13:152–158.
    1. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971;26:240–248. doi: 10.1136/thx.26.3.240.
    1. De Leval MR. The Fontan circulation: a challenge to William Harvey? Nat Clin Pract Cardiovasc Med. 2005;2:202–208. doi: 10.1038/ncpcardio0157.
    1. Gewillig M. The Fontan circulation. Heart. 2005;91:839–846. doi: 10.1136/hrt.2004.051789.
    1. Hosein RBM, Clarke AJB, McGuirk SP, Griselli M, Stumper O, De Giovanni JV, Barron DJ, Brawn WJ. Factors influencing early and late outcome following the Fontan procedure in the current era. The [`]Two Commandments’? Eur J Cardio-Thoracic Surg. 2007;31:344–353. doi: 10.1016/j.ejcts.2006.11.043.
    1. Ono M, Boethig D, Goerler H, Lange M, Westhoff-Bleck M, Breymann T. Clinical outcome of patients 20 years after Fontan operation–effect of fenestration on late morbidity. Eur J Cardiothorac Surg. 2006;30:923–929. doi: 10.1016/j.ejcts.2006.08.025.
    1. McGuirk SP, Winlaw DS, Langley SM, Stumper OF, De Giovanni JV, Wright JG, Brawn WJ, Barron DJ. The impact of ventricular morphology on midterm outcome following completion total cavopulmonary connection. Eur J Cardiothorac Surg. 2003;24:37–46. doi: 10.1016/S1010-7940(03)00186-6.
    1. Idorn L, Olsen M, Jensen AS, Juul K, Reimers JI, Sørensen K, Johnsen SP, Søndergaard L. Univentricular hearts in Denmark 1977 to 2009: Incidence and survival. Int J Cardiol. 2012. [Epub]
    1. Ostrow AM, Freeze H, Rychik J. Protein-losing enteropathy after fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg. 2006;82:695–700. doi: 10.1016/j.athoracsur.2006.02.048.
    1. Diller G-P, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, Johansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis MA. Exercise Intolerance in Adult Congenital Heart Disease: Comparative Severity, Correlates, and Prognostic Implication. Circulation. 2005;112:828–835. doi: 10.1161/CIRCULATIONAHA.104.529800.
    1. D’ Udekem Y, Cheung MMH, Setyapranata S, Iyengar AJ, Kelly P, Buckland N, Grigg LE, Weintraub RG, Vance A, Brizard CP, Penny DJ. How Good Is a Good Fontan? Quality of Life and Exercise Capacity of Fontans Without Arrhythmias. Ann Thoracic Surg. 2009;88:1961–1969. doi: 10.1016/j.athoracsur.2009.07.079.
    1. Paridon SM, Mitchell PD, Colan SD, Williams RV, Blaufox A, Li JS, Margossian R, Mital S, Russell J, Rhodes J. A Cross-Sectional Study of Exercise Performance During the First 2 Decades of Life After the Fontan Operation. J Am Coll Cardiol. 2008;52:99–107. doi: 10.1016/j.jacc.2008.02.081.
    1. La Gerche A, Gewillig M. What Limits Cardiac Performance during Exercise in Normal Subjects and in Healthy Fontan Patients? Int J Pediatr. 2010;2010:1–8.
    1. Gewillig M, Brown SC, Eyskens B, Heying R, Ganame J, Budts W, Gerche AL, Gorenflo M. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thoracic Surg. 2009;10:428–433.
    1. Zongtao Y, Huishan W, Zengwei W, Hongyu Z, Minhua F, Xinmin L, Nanbin Z, Hongguang H. Experimental Study of Nonpulsatile Flow Perfusion and Structural Remodeling of Pulmonary Microcirculation Vessels. Thoracic Cardiovascul Surg. 2010;58:468–472. doi: 10.1055/s-0030-1250124.
    1. Yamagishi M, Kurosawa H, Hashimoto K, Nomura K, Kitamura N. The role of plasma endothelin in the Fontan circulation. J Cardiovasc Surg (Torino) 2002;43:793–797.
    1. Natarajan S, Heiss C, Yeghiazarians Y, Fineman JR, Teitel DF, Tacy TA. Peripheral arterial function in infants and young children with one-ventricle physiology and hypoxemia. Am J Cardiol. 2009;103:862–866. doi: 10.1016/j.amjcard.2008.11.059.
    1. Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008;29:1681–1687. doi: 10.1093/eurheartj/ehn215.
    1. Ovaert C, Thijs D, Dewolf D, Ottenkamp J, Dessy H, Moons P, Gewillig M, Mertens L. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young. 2009. pp. 1–9.
    1. Beghetti M. Fontan and the pulmonary circulation: a potential role for new pulmonary hypertension therapies. Heart. 2010;96:911–916. doi: 10.1136/hrt.2010.193912.
    1. Uzun O, Wong JK, Bhole V, Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg. 2006;82:e39–40. doi: 10.1016/j.athoracsur.2006.08.043.
    1. Stringer WW, Hansen JE, Wasserman K. Cardiac output estimated noninvasively from oxygen uptake during exercise. J Appl Physiol. 1997;82:908–912.
    1. Thomas V, Costes F, Chatagnon M, Pouilly J-P, Busso T. A comparison of lactate indices during ramp exercise using modelling techniques and conventional methods. J Sports Sci. 2008;26:1387–1395. doi: 10.1080/02640410802104920.
    1. Klausen SH, Mikkelsen UR, Hirth A, Wetterslev J, Kjærgaard H, Søndergaard L, Andersen LL. Design and rationale for the PREVAIL study: Effect of e-Health individually tailored encouragements to physical exercise on aerobic fitness among adolescents with congenital heart disease—a randomized clinical trial. Am Heart J. 2012;163:549–556. doi: 10.1016/j.ahj.2012.01.021.
    1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–1619. doi: 10.1016/j.jacc.2009.01.004.
    1. Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM, Rychik J. Impact of Oral Sildenafil on Exercise Performance in Children and Young Adults After the Fontan Operation: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Circulation. 2011;123:1185–1193. doi: 10.1161/CIRCULATIONAHA.110.981746.
    1. Schuuring MJ, Vis JC, Van Dijk APJ, Van Melle JP, Vliegen HW, Pieper PG, Sieswerda GT, De Bruin-Bon RHACM, Mulder BJM, Bouma BJ. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail . 2013. [Epub]
    1. Bowater SE, Weaver RA, Thorne SA, Clift PF. The Safety and Effects of Bosentan in Patients with a Fontan Circulation. Congenital Heart Disease. 2012;7:243–249. doi: 10.1111/j.1747-0803.2012.00635.x.
    1. Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Muscle blood flow is reduced with maintenance of arterial perfusion pressure. Circulation. 1989;80:769–781. doi: 10.1161/01.CIR.80.4.769.
    1. Weber KT, Janicki JS. Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. Am J Cardiol. 1985;55:22A–31A. doi: 10.1016/0002-9149(85)90792-1.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit